Quarterly report (Form 10-Q)
Edwards Lifesciences 10-Q for Quarter ended Sep 30, 2026
Filing excerpt
Intangible and long-lived assets impairment charges of $220.2 million during the three and nine months ended September 30, 2026 were primarily related to the full impairment of a certain in-process research and development asset.